High-dose Chemotherapy for Poor-Prognosis Relapsed Germ-Cell Tumors
Model scores of the 29,894 trials active now.
Model score 24% for any early termination, 10% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 26% of the time (3,728 trials).
Finished trial that started 2008–2014: scored by a model trained without any trial from its start year, so its own outcome was never used.
How it ended
Completed on 2024-01-11, after 2009-06-02 start.
The score above never used this outcome: finished trial that started 2008–2014: scored by a model trained without any trial from its start year, so its own outcome was never used.
Termination over time, as the model saw it at the start
Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2024-01-11. The rest of the way to 100% is still running.
From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.
What moved the score
-
Wording of the registration (title, summary, criteria) (raises risk) · Wording
Phrases that raised it: cellsbraintumorschemotherapytumor
Phrases that lowered it: gemcitabinefev1melphalansafety ofdrugs -
Sponsor's past termination rate: 23.9% (raises risk) · Sponsor's track record
-
Accepts healthy volunteers: No (raises risk) · Who can join
-
Phase: 2 (raises risk) · Design
-
Disease area, cancer: Yes (raises risk) · Disease area
-
Trials the sponsor started in the prior 2 years: 172 (lowers risk) · Sponsor's track record
-
Design: single group (raises risk) · Design
-
Keywords listed: 19 (raises risk) · Design
-
Sponsor type: academic or other (raises risk) · Sponsor's track record
-
Maximum age: 65 (lowers risk) · Who can join
-
Primary purpose: treatment (raises risk) · Design
-
Sponsor's past trials: 184 (lowers risk) · Sponsor's track record
-
Number of arms: 2 (raises risk) · Design
-
Drug's FAERS reports marked serious: 93.1% (raises risk) · Drug's FDA history
-
Drugs with FDA adverse-event history: 7 (raises risk) · Drug's FDA history
-
Drug's FAERS reports with a death: 22.7% (raises risk) · Drug's FDA history
Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.
The trial
Design
- Phase
- 2
- Number of arms
- 2
- Allocation
- non randomized (typical: randomized)
- Design
- single group (typical: parallel)
- Primary purpose
- treatment
- Blinding
- none
- Has a data monitoring committee
- No (typical: 56% yes)
- Responsible party
- sponsor
- Collaborators
- 0
- Keywords listed
- 19 (typical: 1)
Who can join
- Minimum age
- 12 (typical: 18)
- Maximum age
- 65 (typical: 71)
- Sex
- all
- Accepts healthy volunteers
- No (typical: 9% yes)
Sponsor's track record
- Sponsor type
- academic or other
- Sponsor's past trials
- 184 (typical: 32)
- Sponsor's past termination rate
- 23.9% (typical: 9.9%)
- Trials the sponsor started in the prior 2 years
- 172 (typical: 19)
Drug's FDA history
- Drugs with FDA adverse-event history
- 7 (typical: 1)
- Drug has FAERS history
- Yes (typical: 64% yes)
- Drug's FAERS reports before start
- 22143 (typical: 2148)
- Drug's FAERS reports in the prior 12 months
- 4904 (typical: 412.5)
- Drug's FAERS reports marked serious
- 93.1% (typical: 85.6%)
- Drug's FAERS reports with a death
- 22.7% (typical: 15.9%)
Disease area and drugs
- Disease areas
- cancer, urogenital, endocrine
- Drugs matched to FDA substances
- carboplatin, docetaxel, etoposide, gemcitabine, ifosfamide, melphalan, mesna
Typical values are among the trials active now. Sponsor and drug history are counted only up to this trial's start date.
Similar finished trials
- Brentuximab Vedotin in Relapsed/Refractory Germ Cell Tumors NCT02689219 · started 2016 · scored riskier than 91% of active trials terminated
- Dose Intensification Study in Refractory Germ Cell Tumors With Relapse and Bad Prognosis NCT00864318 · started 2009 · scored riskier than 76% of active trials completed
- Study of the Hypomethylating Drug Guadecitabine (SGI-110) Plus Cisplatin in Relapsed Refractory Germ Cell Tumors NCT02429466 · started 2015 · scored riskier than 42% of active trials completed
- Disulfiram and Cisplatin in Refractory TGCTs. NCT03950830 · started 2019 · scored riskier than 86% of active trials completed
- First Line TIP in Poor Prognosis TGCTs. NCT02414685 · started 2015 · scored riskier than 76% of active trials completed
Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.